BioSpace

Novo Slashes GLP-1 Prices Again, Touts New Weight Loss Data on Heels of Lilly Loss

Following Monday’s clinical defeat by Eli Lilly, Novo Nordisk cut the 2027 list prices for its three GLP-1 medicines by as ...
The Pharma Letter

Novo Nordisk partners with Vivtex on next-gen oral obesity and diabetes meds

Novo Nordisk and Vivtex Corporation have entered into a partnership to develop next-generation oral biologic medicines for ...

Popular weight-loss drugs getting cheaper amid price war

Novo Nordisk announced plans to drastically reduce the list price of its versions, Wegovy, Ozempic and Rybelsus.

Eli Lilly slips as Novo to cut list prices for GLP-1 drugs

Eli Lilly (LLY) stock falls as rival Novo Nordisk (NVO) plans to cut Wegovy, Ozempic & Rybelsus U.S. list prices from Jan 1, 2027. Read more here.

Ozempic, Wegovy maker sues Shrewsbury doctor over weight-loss drug

Novo Nordisk is suing a Shrewsbury doctor who sells a cheaper compounded medicine version of its popular Ozempic and Wegovy weight-loss drugs.